Related Experiment Video
Updated: Dec 24, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rapid-Infusion Rituximab in a Pediatric Population
Insights
Rapid rituximab infusions in pediatric patients were evaluated for safety. The 90-minute protocol showed good tolerance with minimal adverse events in non-rheumatic diseases.
Area of Science:
- Pediatric Hematology/Oncology
- Clinical Pharmacology
Background:
- Rituximab is an effective therapy for various pediatric conditions.
- Rapid infusion protocols aim to improve patient convenience and resource utilization.
- Previous studies suggest rituximab is generally safe in pediatric populations.
Purpose of the Study:
- To evaluate the safety and tolerability of a 90-minute rituximab infusion protocol in pediatric patients.
- To assess adverse drug reactions associated with rapid rituximab administration.
- To characterize the patient population receiving rapid rituximab infusions.
Main Methods:
- Retrospective review of 88 rituximab infusions in 22 pediatric patients.
- Primary endpoint: incidence and severity of adverse drug reactions.
- Secondary endpoints: patient demographics, indications, doses, infusion times, and comparison to standard rates.
Main Results:
- No dose-limiting adverse reactions were observed across 88 infusions.
- Three patients experienced mild (Grade 1) infusion-related adverse events.
- Two patients tolerated subsequent rapid infusions; one discontinued therapy.
Conclusions:
- A 90-minute rituximab infusion protocol is well-tolerated in pediatric patients with non-rheumatic diseases.
- The rapid infusion strategy appears safe and feasible for clinical use.
- Minimal infusion-related adverse events were noted, supporting its continued use.
Objectives:
The use of rapid rituximab infusion in certain pediatric populations has generally been regarded as safe. The safety of our institution's rapid rituximab protocol was evaluated.
Methods:
The primary end point was the number of and severity of adverse drug reactions. Secondary end points included a description of the patient population defined by the indication, dose, and number of rituximab infusions administered. Additionally, the difference in infusion times in hours of those receiving rapid rituximab infusions versus the theoretical infusion time of subsequent administration rate schedules was defined.
Results:
A total of 88 infusions for 22 patients were reviewed. No dose-limiting adverse reactions were observed. Three patients experienced grade 1 isolated infusion-related adverse events during a single infusion encounter. Two of the three patients received additional doses of rapid rituximab infusions without incident, whereas the other patient no longer required rituximab therapy.
Conclusions:
The use of a 90-minute rituximab infusion protocol in pediatric patients with non-rheumatic diseases was well tolerated.
More Related Videos
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:29Drug Dosing: Infants and Children
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism